lutetium-177 PSMA
Selected indexed studies
- Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. (N Engl J Med, 2021) [PMID:34161051]
- Lutetium-177 PSMA for the treatment of metastatic castrate resistant prostate cancer: a systematic review. (Expert Rev Anticancer Ther, 2023) [PMID:37194261]
- Extensive preclinical evaluation of lutetium-177-labeled PSMA-specific tracers for prostate cancer radionuclide therapy. (Eur J Nucl Med Mol Imaging, 2021) [PMID:33094433]
_Worker-drafted node — pending editorial review._
Connections
lutetium-177 PSMA is a side effect of
Sources
- [(177)Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. (2021) pubmed
- Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. (2021) pubmed
- Lutetium-177 PSMA for the treatment of metastatic castrate resistant prostate cancer: a systematic review. (2023) pubmed
- Extensive preclinical evaluation of lutetium-177-labeled PSMA-specific tracers for prostate cancer radionuclide therapy. (2021) pubmed
- Lutetium-177-PSMA-617: A Vision of the Future. (2022) pubmed
- Lutetium-177-PSMA-617 or cabazitaxel in metastatic prostate cancer: circulating tumor DNA analysis of the randomized phase 2 TheraP trial. (2025) pubmed
- Dosimetry of [(177)Lu]Lu-PSMA-Targeted Radiopharmaceutical Therapies in Patients with Prostate Cancer: A Comparative Systematic Review and Metaanalysis. (2024) pubmed
- Final overall survival and safety analyses of the phase III PSMAfore trial of [(177)Lu]Lu-PSMA-617 versus change of androgen receptor pathway inhibitor in taxane-naive patients with metastatic castration-resistant prostate cancer. (2025) pubmed
- Quantitative (68)Ga-PSMA-11 PET and Clinical Outcomes in Metastatic Castration-resistant Prostate Cancer Following (177)Lu-PSMA-617 (VISION Trial). (2024) pubmed
- Lutetium-177-PSMA-617 in Metastatic Castration-resistant Prostate Cancer: Limitations of the VISION Trial. (2023) pubmed